ERS Genomics Licenses Genome-Editing Patents to Regeneron Pharmaceuticals
DUBLIN, Ireland, November 24, 2015 - ERS Genomics (ERS) today announced a patent license agreement whereby Regeneron Pharmaceuticals gains access to ERS’ CRISPR-Cas9 genome-editing patents for use in drug discovery and development. ERS Genomics holds rights to foundational CRISPR-Cas9 patent portfolio from Dr. Emmanuelle Charpentier, an inventor of the breakthrough gene-editing technology.
"We are pleased to include Regeneron, a leading biopharmaceutical company, into our portfolio of licensees,” said Shaun Foy, CEO and Founder of ERS Genomics. “Genome editing has many applications in drug discovery and development and making the CRISPR-Cas9 patents widely available to biotechnology and pharmaceutical companies is an important part of ERS Genomics’ strategy."
Dr. Emmanuelle Charpentier’s research unveiled the key components and mechanisms of the CRISPR-Cas9 system, leading to the landmark publication with Jennifer Doudna, (Jinek et al., 2012), which laid the foundation for the use of CRISPR-Cas9 as a highly versatile and precise genome-editing tool.
Financial details of the agreement were not disclosed.
ERS Genomics was formed to provide broad access to the foundational CRISPR-Cas9 intellectual property held by Dr. Emmanuelle Charpentier. Non-exclusive licenses are available for research and sale of products and services across multiple fields including: research tools, kits, reagents; discovery of novel targets for therapeutic intervention; cell lines for discovery and screening of novel drug candidates; GMP production of healthcare products; production of industrial materials such as enzymes, biofuels and chemicals; and synthetic biology. For additional information please visit www.ersgenomics.com.
MacDougall Biomedical Communications